Drugs / LY2090314
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01287520 | Nov 2007 → Apr 2011 | cancer of unknown primary site | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01632306 | Mar 2013 → Jun 2015 | malignant pancreatic neoplasm | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01214603 | Nov 2010 → Dec 2012 | leukemia | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2090314 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01287520 ↗ |
| Action | Inhibit | “LY2090314, a glycogen synthase kinase 3 inhibitor” PMID 26403509 ↗ Sep 20152“Glycogen synthase kinase-3 alpha inhibitor” CHEMBL362558 ↗ “Glycogen synthase kinase-3 beta inhibitor” CHEMBL362558 ↗ |
| Modality | Small molecule | — CHEMBL362558 ↗ |
| Route | Intravenous | “Administered intravenously” NCT01214603 ↗ |
| Target | GSK3A | “Glycogen synthase kinase-3 alpha inhibitor” CHEMBL362558 ↗ |
| Target | GSK3B | “Glycogen synthase kinase-3 beta inhibitor” CHEMBL362558 ↗ |